Evidence map›Paper›PMID 27561088›Full record

ArticleCancer biology & therapy2016

Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma.

Gianmaria Miolo, Alessandra Viel, Vincenzo Canzonieri, Tania Baresic, Angela Buonadonna, Davide Adriano Santeufemia, Della Puppa Lara, Giuseppe Corona

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gianmaria Mioloa Division of Medical Oncology B , IRCCS, National Cancer Institute (CRO) , Aviano , Italy.
Alessandra Vielb Division of Experimental Oncology 1 , IRCCS, National Cancer Institute (CRO) , Aviano , Italy.
Vincenzo Canzonieric Department of Diagnostic Laboratories and Cell Therapy, Division of Pathology , IRCCS, National Cancer Institute (CRO) , Aviano , Italy.
Tania Baresicd Nuclear Medicine Unit, IRCCS National Cancer Institute (CRO) , Aviano , Italy.
Angela Buonadonnaa Division of Medical Oncology B , IRCCS, National Cancer Institute (CRO) , Aviano , Italy.
Davide Adriano Santeufemiae Department of Oncology, Division of Medical Oncology , Sassari Hospital , Sassari , Italy.
Della Puppa Larab Division of Experimental Oncology 1 , IRCCS, National Cancer Institute (CRO) , Aviano , Italy.
Giuseppe Coronaf Department of Translational Research , IRCCS, National Cancer Institute (CRO) , Aviano , Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report an interesting clinical case of a patient carrying a specific BRCA2 germline variant affected by bone and hepatic metastases from a high grade uterine stromal sarcoma who obtained a complete metabolic response after only 3 cycles of trabectedin treatment (1.5 mg/m

Indexed as

Mutation, MissenseAntineoplastic Combined Chemotherapy ProtocolsBase SequenceBone NeoplasmsBRCA2 ProteinDioxolesEndometrial NeoplasmsEpirubicinFemaleGenes, BRCA2Germ-Line MutationHumansIfosfamideLiver NeoplasmsMiddle AgedSarcoma, Endometrial StromalBRCA2 ProteinBRCA2 protein, humanDioxolesEpirubicinIfosfamideTetrahydroisoquinolinesTrabectedinBRCA2 germline variantDNA damagemutationssoft tissue sarcomatrabectedintumor genotype

Identifiers

PMID27561088
PMCPMC5079400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.